Concerta (Methylphenidate) -To-Generic Switch Study
Completed
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1464
- Registration Number
- NCT02730572
A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT02729467
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 1
Completed
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Drug: JNJ-63709178
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT02715011
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Phase 3
Terminated
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT02703272
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT02699606
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02698475
A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-42756493
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02692677
Epidemiology of Treatment Resistant Depression in Taiwan
Completed
- Conditions
- Depressive Disorder, Treatment-Resistant
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8356
- Registration Number
- NCT02691520
Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users
Phase 1
Completed
- Conditions
- Drug Abuse
- Interventions
- Drug: Intravenous placeboDrug: Intranasal placeboDrug: Intravenous racemic ketamineDrug: Esketamine 112 mgDrug: Esketamine 84 mg
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 55
- Registration Number
- NCT02682225
A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02674295
© Copyright 2025. All Rights Reserved by MedPath